ICI 162846

Cat. No.:	HY-101234
CAS No.:	84545-30-2
Molecular Formula:	$C_{11}H_{17}F_3N_6O$
Molecular Weight:	306.29
Target:	Histamine Receptor
Pathway:	GPCR/G Protein; Immunology/Inflammation; Neuronal Signaling
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	ICI 162846 is an orally active antagonist of H_2 receptor. ICI 162846 inhibits acid production accompanied by an increase in the secretion of histamine in chronic duodenal ulcer (CDU) models. ICI 162846 is effective in preventing CDU[1][2].
IC_{50} & Target	H_2 Receptor
In Vivo	ICI 162846 (10 mg/kg, p.o., twice daily for 5 days) reduces the incidence of CDU and inhibits acid production accompanied by an increase in the secretion of histamine in induced CDU models of CFLP mice[2]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	CFLP mice were irradiated to the lower mediastinum to induce CDU[2].
Dosage:	10 mg/kg, twice daily for 5 days
Administration:	Oral gavage (p.o.)
Result:	Reduced the incidence of CDU. Inhibited gastric acid secretion about 50% or more in the basal and the stimulated periods. Induced massive rises in basal (12-fold) and stimulated (9-fold) luminal histamine.

REFERENCES

[1]. Wilson JA, et al. Inhibition of human gastric secretion by ICI 162,846--a new histamine H2-receptor antagonist. Br J Clin Pharmacol. 1986 Jun;21(6):685-9.

[2]. Gompertz RH, et al. Acid blockade by omeprazole or ICI 162846 in a chronic duodenal ulcer model. Agents Actions. 1991 May;33(1-2):161-3.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA